PLGA Nanoparticle Formulation for Your API: A Decision Framework for Polymer Selection
Your API is in hand. You know you need a nanoparticle carrier. Now comes the question that shapes everything downstream: which platform, and which polymer? PLGA (poly lactic-co-glycolic acid) is a biodegradable, FDA-approved copolymer and for programs requiring controlled, sustained release, it’s usually where the conversation starts. Get that decision wrong early, and you’re optimizing a PLGA nanoparticle formulation that was constrained before development began. Here is how experienced developers think through it.
Most teams may not have the full picture.
In practice, most development teams begin their nanoparticle selection with a material already in mind. They've done a literature review and they've likely seen PLGA work for a similar application. Familiarity with a platform is a legitimate selection criterion for PLGA formulation, especially when regulatory precedent matters.
Teams that struggle later in development are often the ones who locked in on a material too quickly. Release profile, loading efficiency, size constraints, targeting requirements: if you haven't ranked your criteria before selecting a nanoparticle platform, the team can spend longer development cycles optimizing towards overly-constrained specifications.
"To match a project to a nanoparticle material, we're listening for things like: they want controlled release of their API (predictable degradation over a specific time period), they want to go with already FDA approved materials, they want improved bioavailability in certain delivery routes. Those signals usually lead us to PLGA." — Diana Dehaini, nanoComposix
When does a PLGA Formulation Make Sense?
PLGA's case rests on properties that are genuinely hard to replicate with other platforms. The degradation is predictable and tunable: PLGA breaks down by hydrolysis of its ester backbone, and you can tune the rate by adjusting the polymer's molecular weight or the ratio of lactic to glycolic acid. Molecular weights of the polymer also play a role in release, higher PLGA molecular weight means slower hydrolysis and a longer release window. Lower molecular weight accelerates it. That predictability is what makes it possible to build a release profile into a particle design rather than characterizing it after the fact. It's also why PLGA has accumulated enough FDA precedent that reviewers understand the material, which can shorten the conversation at the IND stage.
Another critical property is cargo compatibility. Small molecule hydrophobic drugs load efficiently into PLGA nanoparticles via nanoprecipitation or single emulsion, and the formulator's full toolkit stays available: surface modification, PEGylation, targeting ligands, and lipid capping. When the API and the polymer are this compatible, formulation development doesn't require solving a fundamental chemistry problem before addressing the delivery problem.
Where it gets harder: hydrophilic payloads
The limitation of polymeric particles follows directly from what makes them useful: the polymer is hydrophobic. When the payload is hydrophilic you need to work harder with the nanoparticle material. A typical approach is using double emulsion, where a water-in-oil primary emulsion is further emulsified into an external aqueous phase to form a water-in-oil-in-water system. This structure enables entrapment of hydrophilic drugs within internal aqueous compartments.
This double emulsion approach works well and nanoComposix has proven scaling capacities for PLGA nanoparticle formulation using double-emulsion. However, it can add process variables, complicating development in some formulations. Experience in double emulsion is critical to scale up success.
The honest question for any program considering this route is whether the sustained-release benefit justifies that added burden relative to a lipid-based approach. For programs where precise, prolonged release is non-negotiable, it is often beneficial. But for programs where the acceptable window is wide enough that a liposome's burst release in a faster, less controlled manner is acceptable, double emulsion adds cost and development time without a commensurate return.
"Even though it's a slightly more complex process, the benefit is you still have that controlled release -- you're trapping your drug within a polymeric structure that you can control the breakdown of. With lipid nanoparticles, you have a lot less control over where and when it releases." -- Diana Dehaini, nanoComposix
Which tuning variables matter for PLGA nanoparticle formulation?
Once PLGA is the right choice for your program, the PLGA nanoparticle formulation work begins with understanding which variables govern release and how they interact. Selecting PLGA opens a set of interdependent levers, and understanding how they interact is where formulation expertise is required.
Particle composition
PLGA molecular weight governs how quickly the ester backbone hydrolyzes: a 15 kDa PLGA will degrade and release drug faster than a 100 kDa grade (Makadia, 2011). The LA:GA ratio is a finer dial on the same outcome. PLGA 50:50 (equal lactic and glycolic acid) degrades faster than PLGA 75:25, which matters when the difference between a two-week and a six-week release profile is clinically meaningful. Particle size is also critical, where 100 nm nanoparticles might have a profile of days, where a 100 micron particle with the same composition may have a release over weeks to months.
Surface chemistry
Surface chemistry operates on a different axis. PEGylation extends circulation time by reducing protein adsorption and clearance. Targeting ligands steer the particle toward specific tissue types and cell populations. Lipid capping modulates release kinetics at the outer boundary of the particle rather than through bulk degradation.
Particle size
Particle size ties everything together. Smaller particles have higher surface area relative to volume, which accelerates release. Size also influences biodistribution: in IV delivery, particles below 100 nm generally circulate longer, while larger particles are cleared more rapidly by the mononuclear phagocyte system. That target range is typically set by the target biologic mechanism of the API, as well as delivery route. The formulator's job is to hit the required size window without trading away loading efficiency or colloidal stability.
These levers interact, and optimizing one constrains others. A formulator working on PLGA nanoparticles trying to maximize drug loading, meet a tight size specification, and achieve time-specific release simultaneously will face real tradeoffs. The right answer depends entirely on which of those targets is non-negotiable for the program.
The conversation most teams aren't having early enough
The most useful thing a development team can do before engaging a CDMO is force-rank their specifications. Not a wish list of everything they'd like, but a clear answer to which two or three targets the program cannot succeed without, and which ones can flex. Testing the exact limits early on and knowing how much specifications can be compromised before resulting in a change in efficacy saves significant time and budget later in development.
Specification ranking determines polymer selection for your PLGA nanoparticle formulation, manufacturing approach, and where development time gets prioritized. It also protects timelines. Teams that can't articulate their priorities tend to discover tradeoffs one experiment at a time rather than navigating them upfront, which can add months to a development schedule. The perfect process to make the perfect particle can be achieved, but no one has unlimited scale up time. Knowing what is “functional enough” is key.
Work with experts who have seen this before
nanoComposix works with development teams from early platform selection through GMP manufacturing. If you're evaluating nanoparticles for a drug delivery program and want a technical conversation about our nanomedicine development services and which platform fits your API and your goals, reach out.